NICE recommends AbbVie's Rinvoq for atopic dermatitis

29 June 2022

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document recommending Rinvoq (upadacitinib), from US drugmaker AbbVie (NYSE: ABBV), as a treatment of moderate to severe atopic dermatitis (AD) for adults and young people aged 12 and over, if the disease has not responded to at least 1 systemic immunosuppressant, or these are not suitable. Upadacitinib has been recommended alongside two other AD treatments.

AD is a chronic inflammatory skin condition and is the most common form of eczema. AD incidence has increased 2-3 times in the past three decades in industrialized countries. In the UK, 5% of adults aged 18 and over, and 6% of adolescents aged 13-17 years have eczema.

JAK inhibitor Rinvoq pulled in 2021 sales of $1.65 billion, up more than 100% on the prior year, and AbbVie has previously said it expects the drug to achieve revenues of $7.5 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK